Westend Capital Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
VCM
VPM
Westend Capital Management's BMY Position: Q1 2026 in Review
Westend Capital Management reduced its Bristol-Myers Squibb (BMY) stake by 8.5% in Q1 2026, selling an estimated $3.32K and leaving 611 shares worth $37.1K. The position accounts for 0.01% of the portfolio, ranked #104.
Westend Capital Management first reported a position in BMY in Q4 2024 and has held it in 6 quarters since. The position peaked at $40.7K in Q1 2025. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Westend Capital Management held 611 shares of Bristol-Myers Squibb worth $37.1K as of Q1 2026.
- Westend Capital Management sold 57 Bristol-Myers Squibb shares in Q1 2026, an estimated $3.32K.
- Bristol-Myers Squibb made up 0.01% of Westend Capital Management's portfolio in Q1 2026, its #104 holding.
- Westend Capital Management first reported a position in Bristol-Myers Squibb in Q4 2024 and has held it in 6 quarters since.
- Westend Capital Management's Bristol-Myers Squibb position peaked at $40.7K in Q1 2025.
- 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Westend Capital Management's 13F filing for Q1 2026, filed 14 Apr 2026.